Introduction: Dientamoeba fragilis infection in children is common, and its incidence has increased since the introduction of more sensitive molecular techniques. There is no consensus on the optimal treatment. Current medical practice in the Netherlands is to treat symptomatic children with clioquinol or metronidazole. This study attempts to obtain more information about the clinical picture of D. fragilis infection in children and to evaluate responses to both antiparasitic drugs.
Methods: Children <18 years of age with a positive stool polymerase chain reaction test for D. fragilis infection were retrospectively evaluated. Clinical data and effectiveness of treatment were analyzed by examining patient’s hospital records from the Medical Centre Leeuwarden by repeated analysis of stool samples by the Centre for Infectious Diseases in Friesland.
Results: We analyzed 238 patients with an average age of 8.5 years (±4.2 years). Most patients were symptomatic (95.8%) and presented with abdominal pain (72.7%), loose stools (32.8%) and hard stools (24.8%). Coinfection with other gastrointestinal pathogens was present in 29 patients (12.2%). A higher incidence of infection was found in the winter. Clioquinol had a higher clinical success rate than metronidazole (74.7% versus 55.2%, P = 0.047).
Conclusion: These results suggest that clioquinol could be more effective than metronidazole in alleviating symptoms of D. fragilis infection in children, but double-blind prospective placebo-controlled studies should be performed before final conclusions can be made.
From the *University Medical Centre Utrecht, Utrecht; †Antonius Hospital, Sneek; and ‡Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Accepted for publication November 21, 2012.
The authors have no funding or conflicts of interest to disclose.
Address for correspondence: Janna M. A. ter Schure, MD, Wilhelmina Kinderziekenhuis, University Medical Centre Utrecht, Post Office Box 85090, 3508 AB, Utrecht, The Netherlands. E-mail: firstname.lastname@example.org.